226 related articles for article (PubMed ID: 29420369)
21. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review.
Gamulin M; Nham E; Rkman D; Antunac Golubić Z; Likić R
Croat Med J; 2020 Aug; 61(4):326-332. PubMed ID: 32881430
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma.
Giuliani J; Bonetti A
Clin Genitourin Cancer; 2018 Jun; 16(3):e557-e562. PubMed ID: 29534940
[TBL] [Abstract][Full Text] [Related]
24. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
Sarfaty M; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Apr; 73(4):628-634. PubMed ID: 28807351
[TBL] [Abstract][Full Text] [Related]
25. Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions.
Ishihara H; Kondo T; Takagi T; Yoshida K; Okumi M; Tanabe K
Int J Urol; 2019 Aug; 26(8):849-850. PubMed ID: 31115103
[No Abstract] [Full Text] [Related]
26. Safe use of nivolumab in a patient with renal cell carcinoma and hepatitis B.
Akar E; Baytekin HF; Deniz H; Tural D
J Oncol Pharm Pract; 2020 Jun; 26(4):1022-1024. PubMed ID: 31635548
[TBL] [Abstract][Full Text] [Related]
27. [Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].
Rexer H; Steiner T; Bergmann L
Urologe A; 2017 Jun; 56(6):802-803. PubMed ID: 28536740
[No Abstract] [Full Text] [Related]
28. Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment.
Tabei T; Natsume I; Kobayashi K
Int J Urol; 2017 Sep; 24(9):708-710. PubMed ID: 28734029
[TBL] [Abstract][Full Text] [Related]
29. Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab.
Adra N; Cheng L; Pili R
Clin Genitourin Cancer; 2017 Jun; 15(3):e517-e519. PubMed ID: 28110836
[No Abstract] [Full Text] [Related]
30. Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.
Spaas M; Sundahl N; Ost P
Eur Urol; 2022 Feb; 81(2):216. PubMed ID: 34810013
[No Abstract] [Full Text] [Related]
31. [Initial Clinical Experience of Nivolumab for Metastatic Renal Cell Carcinoma].
Fukunaga A; Yamasaki T; Okuno T; Imai K; Ikeuchi R; Hishiki K; Goto T; Sawada A; Negoro H; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
Hinyokika Kiyo; 2018 Oct; 64(10):383-389. PubMed ID: 30543735
[TBL] [Abstract][Full Text] [Related]
32. Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.
Beulque Y; Deleu AL; Punie K; De Wever L; Baldewijns M; Caruso S; Couchy G; Zucman-Rossi J; Beuselinck B
Clin Genitourin Cancer; 2019 Oct; 17(5):e909-e912. PubMed ID: 31378579
[No Abstract] [Full Text] [Related]
33. Eruptive keratoacanthomas secondary to nivolumab immunotherapy.
Bednarek R; Marks K; Lin G
Int J Dermatol; 2018 Mar; 57(3):e28-e29. PubMed ID: 29318617
[No Abstract] [Full Text] [Related]
34. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Escudier B; Sharma P; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Gurney H; Donskov F; Peltola K; Wagstaff J; Gauler TC; Ueda T; Zhao H; Waxman IM; Motzer RJ;
Eur Urol; 2017 Dec; 72(6):962-971. PubMed ID: 28262413
[TBL] [Abstract][Full Text] [Related]
35. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
[No Abstract] [Full Text] [Related]
36. Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions.
Ishihara H; Fukuda H; Takagi T; Kondo T; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
Int J Urol; 2021 Jan; 28(1):99-106. PubMed ID: 33159426
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.
Thibault C; Vano Y; Soulat G; Mirabel M
Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497
[No Abstract] [Full Text] [Related]
38. [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)].
Rexer H
Urologe A; 2015 Oct; 54(10):1443-5. PubMed ID: 26350358
[No Abstract] [Full Text] [Related]
39. Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.
Vitale MG; Baldessari C; Milella M; Buti S; Militello AM; Di Girolamo S; Fornarini G; Perri G; Basso U; Maruzzo M; Porta C; Cosmai L; Pipitone S; Cerma K; Cascinu S; Sabbatini R
Clin Genitourin Cancer; 2019 Oct; 17(5):e903-e908. PubMed ID: 31375351
[No Abstract] [Full Text] [Related]
40. Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment.
Yanagihara T; Tanaka K; Ota K; Kashiwagi E; Takeuchi A; Tatsugami K; Eto M; Nakanishi Y; Okamoto I
Ann Oncol; 2017 Aug; 28(8):2038-2039. PubMed ID: 28459940
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
